论文部分内容阅读
目的:探讨奥扎格雷对进展性脑血栓形成患者血小板活化功能变化的影响。方法:68例颈内动脉系统进展性脑血栓形成患者随机分为奥扎格雷治疗组和丹参治疗组。应用流式细胞仪和单克隆抗体动态测定CD62p、CD63,行血小板活化指标和临床疗效对照观察。结果:进展性脑血栓形成患者发病早期(24h内)CD62p、CD63值较对照组显著增高(P<0.001)。患者经丹参治疗后,血小板表达CD62p、CD63缓慢下降,14d时其值仍高于健康对照组(P<0.05)。经奥扎格雷治疗后血小板表达CD62p、CD63快速下降,至14d时已接近健康对照组(P>0.05)。奥扎格雷组临床疗效明显优于丹参组。结论:进展性脑血栓形成患者中血小板表达CD62p、CD63明显增加,并与病情转归相关。奥扎格雷治疗后可使CD62p、CD63快速下降、提高临床疗效。
Objective: To investigate the influence of ozagrel on the changes of platelet activation in patients with progressive cerebral thrombosis. Methods: Sixty-eight patients with progressive cerebral thrombosis of internal carotid artery were randomly divided into two groups: Ozagrel treatment group and Salvia miltiorrhiza treatment group. Using flow cytometry and monoclonal antibodies dynamic determination of CD62p, CD63, platelet activation indicators and the clinical efficacy of controlled observation. Results: The CD62p and CD63 values in patients with progressive cerebral thrombosis at the early stage of onset (24h) were significantly higher than those in the control group (P <0.001). After treatment with Salvia miltiorrhiza, the expression of platelet CD62p and CD63 decreased slowly, which was still higher than that of the healthy control group on the 14th day (P <0.05). Platelets after treatment with ozagrel significantly decreased CD62p and CD63 levels, and were close to healthy controls at 14 days (P> 0.05). Ozagrel group significantly better clinical efficacy than Salvia group. Conclusion: Platelet expression of CD62p and CD63 in patients with progressive cerebral thrombosis is significantly increased, which is related to the prognosis of patients. Ozagrel treatment can make CD62p, CD63 rapid decline, improve clinical efficacy.